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In acute promyelocytic leukemia (APL), the promyelocytic leukemia (PML) protein is fused to the retinoic acid receptor
alpha (RAR). Arsenic is an effective treatment for this disease as it induces SUMO-dependent ubiquitin-mediated
proteasomal degradation of the PML-RAR fusion protein. Here we analyze the nuclear trafﬁcking dynamics of PML and
its SUMO-dependent ubiquitin E3 ligase, RNF4 in response to arsenic. After administration of arsenic, PML immediately
transits into nuclear bodies where it undergoes SUMO modiﬁcation. This initial recruitment of PML into nuclear bodies
is not dependent on RNF4, but RNF4 quickly follows PML into the nuclear bodies where it is responsible for
ubiquitylation of SUMO-modiﬁed PML and its degradation by the proteasome. While arsenic restricts the mobility of
PML, FRAP analysis indicates that RNF4 continues to rapidly shuttle into PML nuclear bodies in a SUMO-dependent
manner. Under these conditions FRET studies indicate that RNF4 interacts with SUMO in PML bodies but not directly
with PML. These studies indicate that arsenic induces the rapid reorganization of the cell nucleus by SUMO modiﬁcation
of nuclear body-associated PML and uptake of the ubiquitin E3 ligase RNF4 leading to the ubiquitin-mediated degra-
dation of PML.
INTRODUCTION
The promyelocytic leukemia protein (PML) was originally
identiﬁed in acute promyelocytic leukemia (APL), where it
is fused to the retinoic acid receptor  (RAR) as a result of
the t(15;17) chromosomal translocation (de The ´ et al., 1990;
de The et al., 1991; Kakizuka et al., 1991). Fusion of PML to
RAR causes leukemia as it blocks differentiation of hema-
topoietic progenitor cells. In cells containing PML-RAR the
fusion protein is dispersed into a large number of small
nuclear bodies but in normal cells PML forms discrete nu-
clear structures named PML nuclear bodies (PML NBs),
which harbor numerous other transiently or permanently
localized proteins including Daxx, Sp100, SUMO-1, and p53
(Weis et al., 1994; Dyck et al., 1994; Bernardi and Pandolﬁ,
2007). Arsenic is successfully used to treat APL (Wang and
Chen, 2008), but it is only recently that the mechanism of
action of arsenic has been clariﬁed. Arsenic leads to SUMO-
dependent ubiquitin-mediated proteolysis of the PML-RAR
fusion protein (Tatham et al., 2008; Lallemand-Breitenbach et
al., 2008). This is mediated by Ring ﬁnger protein 4 (RNF4),
also known as Small Nuclear RING Finger (SNURF), a mem-
ber of the family of SUMO Targeted Ubiquitin Ligases
(STUbLs) (Perry et al., 2008; Geoffroy and Hay, 2009). Orig-
inally identiﬁed as a coactivator of androgen receptor (Moil-
anen et al., 1998), human RNF4 encodes a protein of 194 aa
that contains a RING domain (Hakli et al., 2004) and multiple
SUMO interaction motifs (SIM) (Tatham et al., 2008). RNF4
interacts strongly with polySUMO chains due to the pres-
ence of multiple SIM in its N-terminal region (Tatham et al.,
2008) and can be found associated with SUMO in PML
bodies (Hakli et al., 2005). Indeed, RNF4 has the ability to
ubiquitylate polySUMO chains conjugated to PML and tar-
get the protein for ubiquitin-mediated proteolysis (Tatham
et al., 2008; Lallemand-Breitenbach et al., 2008). In cells de-
pleted of RNF4, PML protein accumulates and arsenic treat-
ment fails to induce the degradation of PML resulting in the
accumulation of SUMO-modiﬁed PML in nuclear bodies
(Tatham et al., 2008).
PML is a multifunctional protein that plays an essential
role in regulating diverse cellular processes including tumor
suppression, apoptosis, cell cycle regulation, senescence,
transcriptional regulation, DNA damage, and genome sta-
bility (Bernardi and Pandolﬁ, 2007). In human cells, the
primary transcript of the PML gene generates a number of
alternatively spliced mRNAs, each of which encodes a dis-
tinct protein (Jensen et al., 2001). Seven PML isoforms have
been classiﬁed based on C-terminal variation but many of
the detailed studies have been performed with PML isoform
III. PML, also known as TRIM19, contains the characteristic
RBCC motif, which consists of a RING domain adjacent to
two zinc-coordinating B-boxes and a coiled-coil domain.
These motifs are required for the localization of PML within
the PML nuclear body (NB) and the recruitment of other
PML NBs-associated proteins (Bernardi and Pandolﬁ, 2007).
Formation of PML NBs depends also on the posttransla-
tional modiﬁcation of PML with Small ubiquitin modiﬁer
(SUMO), a member of ubiquitin family. Indeed, PML is
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4227sumoylated on three lysine residues and PML mutants that
cannot be sumoylated are unable to form proper PML NBs
(Ishov et al., 1999). A requirement for SUMO modiﬁcation in
the genesis of PML NBs is also evident from genetic studies
in cells derived from mouse blastocysts that are unable to
carry out SUMO modiﬁcation as a result of deletion of the
gene encoding UBC9, the single E2 conjugating enzyme
responsible for SUMO modiﬁcation. These cells have dra-
matic defects in PML body organization, demonstrating
that SUMO modiﬁcation is required for the normal func-
tion of PML bodies (Nacerddine et al., 2005). This is sup-
ported by the observation that loss of SUMO-1 in mice
affects PML expression levels and PML NB formation
(Evdokimov et al., 2008). In addition, PML contains a phos-
pho-regulated SUMO-interacting motif (SIM) in its C termi-
nus that mediates interaction with other SUMOylated pro-
teins and promotes their recruitment in PML NBs (Shen et
al., 2006; Stehmeier and Muller, 2009). SUMO modiﬁcation
of PML protein is induced in many situations including
stress responses, viral infection, and expression of proteins
such as HDAC7 (Saitoh and Hinchey, 2000; Pampin et al.,
2006; Gao et al., 2008). Increased SUMO modiﬁcation of PML
is evident after arsenic treatment and is accompanied by
transit of PML from the nucleoplasm to PML NBs (Zhu et al.,
1997; Lallemand-Breitenbach et al., 2001; Tatham et al., 2008;
Lallemand-Breitenbach et al., 2008).
To analyze the dynamic interplay between PML, SUMO,
and RNF4 in response to arsenic we have created ﬂuores-
cent-tagged versions of these proteins and used them for
real-time ﬂuorescence microscopy to follow changes in traf-
ﬁcking, interactions, and ultimately degradation of PML.
Our data demonstrate that after exposure of cells to arsenic
PML undergoes rapid SUMO modiﬁcation and is recruited
into PML NBs independently of RNF4. This is followed by
the accumulation of RNF4 in PML NBs, but Fluorescence
Resonance Eneregy Transfer (FRET) experiments indicate
that RNF4 was recruited by the SUMO modiﬁcation on PML
rather than directly by PML. Subsequent RNF4-mediated
ubiquitylation leads to the proteasomal degradation of PML.
Thus, the arsenic-induced SUMO modiﬁcation of PML ini-
tiates a rapid reorganization of the cell nucleus leading to
Figure 1. Establishment and characteriza-
tion of HeLa PML-YFP stable cell line. (A)
Schematic showing the nuclear isoforms of
PML that share the same N-terminal region
but differ in their C termini due to the alter-
native splicing of exons 7–9. Nuclear PML
isoforms I to V harbor three SUMOylation
sites (K65, K160, and K490), a SUMO-interact-
ing motif (SIM), a nuclear localization signal
(nls), and a RBCC motif containing a RING
ﬁnger domain (R) adjacent to two zinc coor-
dinating B-boxes and a coiled-coil domain
(CC). PML VI differs from the other PML
isoforms due the absence of a SIM domain.
(B) Whole cell extracts from parental HeLa
cells and HeLa PML-YFP were analyzed by
SDS-PAGE followed by Western Blot using a
rabbit anti-PML antibody. An anti-actin anti-
body was used as a control of loading. (C)
HeLa were stably transfected with a plasmid
expressing PML-YFP placed under the con-
trol of EF1 promoter. Endogenous PML in
parental HeLa cells (wt) was detected with a
chicken antibody to PML and PML in cells
stably expressing the PML-YFP fusion protein
was detected by immunoﬂuorescence using a
mouse anti-PML antibody whereas expres-
sion of the ﬂuorescent-tagged PML protein
was visualized by YFP ﬂuoresence. DNA was
stained with DAPI. Bar, 5 m. (D). Graph show-
ing the number of PML bodies in HeLa wt and
HeLa PML-YFP. (E) Cell cycle analysis of HeLa
and HeLa PML-YFP cell lines was determined
by ﬂow cytometry. The percentage of cells in
G1, S and G2/M phase was determined by
measuring the intensity of DNA staining with
propidium iodide (FL2-H).
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to the degradation of PML and dissolution of PML NBs.
MATERIALS AND METHODS
Plasmids and DNA Constructs
The enhanced yellow ﬂuorescent protein (YFP) or cyan-ﬂuorescent protein
(CFP) were used to construct ﬂuorescent-tagged versions of PML, RNF4, or
SUMO-2 (See Table S1 in Supplemental Material). Human PMLIII (accession
number AAB19601) or rat RNF4 (accession number NM_019182) were am-
pliﬁed by PCR from pcDNA3.1 to generate SalI and BamHI sites ﬂanking the
sequence. PCR products were then digested with the appropriate enzymes
and inserted in place of H2B into either pBOS-H2B-YFP or pBOS-H2B-CFP
vectors (Leung et al., 2004). These vectors contain the mammalian EF1
promoter to drive expression of the ﬂuorescent-tagged protein and harbor
the blasticidin resistance gene as a selection marker. Fluorescent-tagged
RNF4 mutants (RNF4-CS1 and RNF4 mtSIM1, 2, 3, 4) were obtained
according to the strategy described above. Human SUMO-2 full-length
(accession number CAG46970) was ampliﬁed by PCR to generate EcoRI
and BamHI sites ﬂanking the sequence. PCR product was inserted in the
C-terminal region of EGFP into the pEGFP-C1 plasmid (Clontech, Palo
Alto, CA).
Antibodies
Antigen afﬁnity puriﬁed sheep SUMO-1, sheep SUMO-2, chicken RNF4, and
chicken PML antibodies were prepared in house. Mouse anti–-actin (Sigma,
St. Louis, MO) and mouse anti-GFP (clones 7.1 and 13.1, Roche, Indianap-
olis, IN) were obtained from commercial sources. Rabbit anti-RNF4, mouse
anti-PML 5E10, rabbit anti-PML, mouse anti-p53 (DO-1), and mouse anti-
nucleolin antibodies were a kind gifts from Jorma Palvimo (University of
Kuopio, Finland), Roel van Driel (University of Amsterdam, The Nether-
lands), Anne Dejean (Institute Pasteur, Paris, France), David Lane (Uni-
versity of Dundee, Scotland), and Ara Hovanessian (University of Paris,
France), respectively.
Cell Culture and Immunoﬂuorescence Analysis
HeLa cells were cultured in DMEM (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal calf serum (GIBCO BRL, Grand Island, NY) in a 10% CO2
atmosphere at 37°C. To establish PML-YFP stable cell line, HeLa cells were
grown in 10-cm Petri dishes to 50% of conﬂuence and were transfected the
next day with the ﬂuorescent-tagged PML-YFP plasmid using Fugene 6
(Roche) according to the manufacturer’s directions. Two days posttransfec-
tion, 1 g/ml blasticidin was added to select cells stably expressing the fusion
protein. Fluorescent cells were then sorted using a FACS Vantage SE cell
sorter with DIVA option (BD Biosciences, San Jose, CA) with a helium-neon
laser at 488 nm. The same protocol of transfection was used to establish the
HeLa YFP-SUMO-2 cell line, except that 100 g/ml neomycin was used to
select resistant clones.
For immunoﬂuorescence experiments, cells were seeded onto coverslips
and were ﬁxed with 4% paraformaldehyde for 10 min, at room temperature.
Cells were then permeabilized with 0.2% Triton for 10 min and were blocked
in PBS containing 5% BSA and 0.1% Tween for 30 min. Primary and second-
ary antibodies diluted in PBS with 1% BSA and 0.1% Tween were successively
added on the cells for 1h. Cells were then stained 0.1 g/ml DAPI and were
mounted in Vectashield mounting medium.
Cell Cycle Analysis
Hela cells or HeLa PML-YFP cell line were trypsinized and washed with PBS
before ﬁxation with cold 70% ethanol for2ha t4°C. Cells were centrifuged at
Figure 2. Effect of RNF4 on arsenic-induced
PML degradation in real time. (A) Time lapse
experiments were performed on HeLa PML-
YFP stable cells transfected with a nontarget
siRNA (siNT) or a siRNA against RNF4
(siRNF4) and exposed to 1 M arsenic for 18h.
PML-YFP was imaged in real time by ﬂuores-
ence microscopy over 15 h by collecting a
stack of 20 sections with the YFP channel
(green) and one image with the differential
interference contrast (DIC) every 15 min. The
projected z-sections collected in YFP channel
were merged to the respective DIC image to
monitor the position of PML NB within the
cells. Bar, 5 M. (B) Fluorescence intensity of
PML bodies was quantiﬁed by deﬁning a re-
gion of interest containing one PML body and
comparing it a region in the nucleoplasm.
Relative ﬂuorescence intensity represents the
difference of intensities between these two
regions. The graph shows mean values from
at least 10 cells. (C) Whole cell extracts from
PML-YFP HeLa cells transfected with siRNA
to RNF4 or a nontarget siRNA were analyzed
by SDS PAGE followed by Western Blotting
with a chicken anti-PML antibody to show the
accumulation of PML in the absence of RNF4.
Depletion of RNF4 was controlled with a rab-
bit anti-RNF4 antibody. (D) Nuclear extracts
from PML-YFP HeLa cells either untreated or
exposed to 1 uM arsenic for 1 h were incu-
bated with GFP-trap beads and bound pro-
teins collected. Proteins were eluted from the
beads and analyzed by SDS-PAGE followed
by Western blotting with antibodies against
PML, GFP, SUMO-1, SUMO-2, and ubiquitin
to evaluate proteins bound to PML-YFP. The
input represents 10% of the nuclear lysate.
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containing 50 mg/ml propidium iodide (PI), 50 g/ml RNAseA and 0.1%
(vol/vol) Triton X-100 for 30 min. The intensity of DNA staining (FLH-2) was
determined by ﬂow cytometry on a FACS Calibur (Becton Dickson, San
Diego, CA) to determine the percentage of cells in G1, S, and G2/M phases.
Protein Extraction and Western Blot Analysis
Cells were lysed in 2 Laemmli lysis buffer (150 mM Tris-HCL (pH 6.8), 5%
(wt/vol) SDS, 25% (vol/vol) glycerol, and 0.01% (wt/vol) bromophenol blue)
supplemented with 10 mM iodoacetamide. Lysates were clariﬁed by sonica-
tion for 10 s on low power (Branson digital soniﬁer 450) and protein concen-
tration was determined by using the BCA assay kit (Thermo Scientiﬁc).
-mercaptoethanol was added to a ﬁnal concentration of 0.75 M into each
sample. Total cellular protein was subjected to SDS-polyacrylamide gels
electrophoresis (SDS-PAGE) and transferred onto Hybond membrane for
Western blot analysis.
Immunoprecipitation
For immunoprecipitation of PML-YFP protein, nuclear extracts were pre-
pared from HeLa cells stably expressing PML-YFP grown in 10-cm Petri
dishes. After scraping into the medium, cells were washed twice in PBS
containing 100 mM iodoacetamide and were collected by centrifugation at
1500 rpm for 5 min. Cells were resuspended in ice cold buffer A (10 mM
HEPES pH 7.9, 1.5 mM MgCl2,10 mM KCl, complete protease inhibitor
cocktail tablets (Roche), 200 mM iodoacetamide) and were disrupted by using
a syringe to pass them through a narrow (26 gauge) needle. Nuclei were
separated from the cytoplasmic fraction by centrifugation at 3200 rpm for 5
min at 4°C, washed twice with buffer A, and resuspended in RIPA buffer (50
mM Tris pH 6.8, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 10 mM
iodoacetamide). Nuclear extract was sonicated and clariﬁed by centrifugation
at 13,000 rpm for 1 min. The nuclear supernatant was precleared with Sepha-
rose beads before incubation with GFP-trap beads (Chromotek) for2ha t4°C.
Beads were collected by centrifugation at 3200 rpm and washed twice with
RIPA buffer. Proteins were eluted by adding 2 SDS lysis buffer and analyzed
by Western blotting.
Treatment of Cells with Cycloheximide
To inhibit protein synthesis, HeLa cells were grown in six-well plates for 24 h
before addition of fresh medium containing 50 g/ml cycloheximide. Cells
were harvested at different times after cycloheximide treatment and subjected
to SDS-PAGE and Western blot analysis to detect RNF4, p53 and actin
proteins. To carry out real-time imaging, 50 g/ml cycloheximide and 1 M
arsenic in Leibovitz’s L-15 medium (Invitrogen) supplemented with 10% fetal
bovine serum was added to PML-YFP cells seeded in Labtek chamber slides.
Quantitative Reverse Transcription-PCR
To quantify endogenous Rnf4 transcripts during arsenic treatment, total RNA
was extracted from HeLa cells stably expressing PML-YFP using an SV total
RNA isolation kit (Promega). Total cDNAs were ampliﬁed with a SuperScript
II reverse transcriptase kit (Invitrogen), and real-time quantitative PCR was
performed using a TaqMan system for 40 cycles of 15 s at 95°C and 1 min at
60°C with an ABI 7700 instrument (Applied Biosystems). TaqMan probes
used for detection of human RNF4 and the internal control actin were pur-
chased from Applied Biosystems (Hs00231302_m1 RNF4, Hs99999903_ml
ACTB).
Live-Cell Imaging in Real Time and Measurement of
Fluorescence Intensities
For live-cell imaging experiments, HeLa cells were seeded onto Lab-Tek II
four-chamber slides (Nalgen Nunc) and transfected the next day with the
appropriate ﬂuorescent-tagged proteins using Fugene 6 (Roche). HeLa cells
stably expressing ﬂuorescently tagged fusion proteins were seeded in the
same way. When required, double-stranded small interfering RNA (siRNA)
for RNF4 or control scrambled sequence (Dharmacon, Lafayette, CO) were
introduced at 5 nM ﬁnal concentration using Lipofectamine RNAiMAX (In-
vitrogen). Two days later, cells were changed into Leibovitz’s L-15 medium
(Invitrogen) supplemented with 10% fetal bovine serum. Images were col-
lected using the DeltaVision microscope system (Applied Precision) with an
Olympus IX70 microscope and a cooled CCD camera (Coolsnap HQ, Photo-
metrics). Temperature was maintained at 37°C using an environmental cham-
ber (Solent Scientiﬁc, Segensworth, UK). Stacks of 20 sections with z-step set
to 400 nm were collected in different channels with 35–50 ms exposure with
a Plan Apo 60  1.40 numerical aperture objective lens (Olympus). A single
z-section was captured by differential interference contrast microscopy (DIC)
to visualize the position of PML NB within the cells during arsenic treatment.
Collected images were deconvolved with SoftWoRx (Applied Precision), and
z-stack projections were made before merging with the optical section. Be-
cause PML structures were mobile, a region of interest (ROI) containing one
PML body has been deﬁned at each time point to measure ﬂuorescence
intensities using OMERO Beta-4.3 software. The intensities in a random
region outside the nucleoplasm divided by the region of interest was taken as
the value to which the intensities within the PML nuclear body were com-
pared. Data were collected from around 20 cells.
Fluorescence Recovery after Photobleaching
Fluorescence recovery after photobleaching (FRAP) experiments were carried
out on the same slides and microscope described above. Entire PML NBs were
bleached with a 488-nm argon laser at 50% laser intensity to reduce the YFP
signal by 90%. A nucleoplasmic region outside PML NB was also bleached as
a control. Images were taken before the bleach pulse and image acquisition
after bleaching was adjusted according to the recovery of the ﬂuorescent
proteins by using 0.05% laser transmission intensity to minimize scan bleach-
ing. As PML recovers slowly after photobleaching, 300 images were collected
at 1-min intervals over a 10 min period whereas 32 images were captured for
RNF4 within 11 s. Projection of z-sections were made only for PML. The
ﬂuorescence intensity was measured in bleached PML NBs and in control
Figure 3. Subcellular localization of SUMO-2
during arsenic treatment. (A) Characteriza-
tion of HeLa YFP-SUMO-2 cell line. HeLa
cells were stably transfected with a plasmid
expressing a YFP-SUMO-2 fusion protein.
Whole cells extracts from both parental HeLa
and stable YFP-SUMO-2 cells were analyzed
by SDS-PAGE followed by Western blot with
rabbit anti-SUMO-2 and mouse anti-GFP an-
tibodies. (B) HeLa YFP-SUMO-2 stable cell
line was transfected with siRNA to RNF4 or a
control nontargeting si RNA (NT) for 48 h
before adding 1 M of arsenic. Whole cell
extracts were analyzed by SDS-PAGE fol-
lowed by Western Blotting with rabbit anti-
SUMO-2 and chicken anti-PML antibodies.
Depletion of RNF4 was controlled with a rab-
bit anti-RNF4 antibody. (C) Subcellular local-
ization of SUMO-2 during arsenic treatment.
YFP-SUMO-2 HeLa cells were transfected
with siRNA to RNF4 or a control nontarget-
ing siRNA (NT) and YFP ﬂuorescence mea-
sured for 18 h after the addition of 1 Mo f
arsenic. Images shows a projection of z-sec-
tions collected into YFP channel at selected
time points. Bar, 5 M.
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The ﬂuorescence intensity in the bleached PML was normalized to the non-
bleached signal after substraction of the background signal. Data were col-
lected from ten PML NBs.
Fluorescence Resonance Energy Transfer Acceptor
Photobleaching
Fluorescence resonance energy transfer (FRET) was measured by acceptor
photobleaching method as previously described (Ellis et al., 2008). The FRET
experiment was conducted on a DeltaVision microscope system (Applied
Precision) ﬁtted with a quantiﬁable laser module, including a 20-mW 532-nm
CW laser, suitable for photobleaching YFP without cobleaching CFP. Fluo-
rescence of the donor (CFP) was observed by using argon laser 436/10 nm
excitation and 480/40 band-pass emission ﬁlters, whereas ﬂuorescence of
acceptor (YFP) was observed using argon laser 532 nm excitation and 580/70
band-pass emission ﬁlters. Images were collected with a Plan-Apochromat
100  1.35 numerical aperture lens (Olympus) and a cooled CCD camera
(CoolSnap HQ; Photometrics).
Photobleaching of YFP ﬂuorescence was achieved by irradiation of the
region of interest containing one PML NB with the 532 nm excitation ﬁlter at
50% laser intensity. A nucleoplasmic region of the same area was bleached as
a negative control, resulting in minimal CFP bleaching (0–2%) which has not
been taken into account for the calculation of FRET efﬁciency. CFP ﬂuores-
cence was measured before (CFPbefore) and after (CFPafter) the YFP bleach-
ing by collecting a total of 23 images. Pixel intensities of the different regions
were analyzed with OMERO software and apparent FRET efﬁciency was
expressed as the percent increase of prebleach CFP ﬂuorescence in the region
of interest compared with that observed after YFP photobleaching, according
to the equation: FRET efﬁciency [%]  (CFPafter  CFPbefore)  100/CFPafter,
previously described by Stanek et al. (Stanek and Neugebauer, 2004). P value
was calculated with the two-tailed homoscedastic t test comparing the FRET
efﬁciencies with and without As2O3 treatment.
RESULTS
Establishment of YFP-PML HeLa Stable Cell Line
We have shown previously that the RING domain containing
protein RNF4 targets SUMO modiﬁed PML for ubiquitin-me-
diated proteolysis after exposure of cells to arsenic (Tatham et
al., 2008). To investigate the cellular mechanisms involved in
arsenic-induced PML degradation, we generated a HeLa cell
line stably expressing a ﬂuorescent version of PML that allows
the degradation of PML to be quantiﬁed in real-time. Although
multiple nuclear isoforms of PML have been reported (Figure
1A), isoform III is the only one which has been extensively
studied upon arsenic treatment. We therefore created a fusion
of the PML III isoform with yellow ﬂuorescent protein (YFP)
and selected HeLa cells stably expressing the fusion protein.
Cells expressing levels of PML-YFP comparable to that of
endogenous PML were obtained by FACS. Analysis of the
PML-YFP cells and the parental HeLa cells by immunoﬂuores-
cence after staining with a PML antibody and by YFP ﬂuores-
cence revealed that the PML-YFP HeLa cells displayed similar
numbers of PML bodies and that PML-YFP was efﬁciently
incorporated into PML subnuclear bodies (Figure 1, C and D).
Figure 4. Inhibition of RNF4 synthesis
blocks arsenic-induced PML degradation. (A
and B) Arsenic fails to induce the degradation
of PML when protein translation is inhibited.
HeLa PML-YFP stable cells were incubated
with 1 M arsenic and 50 g/ml cyclohexi-
mide and analyzed by ﬂuorescence micros-
copy for 16h (A). A stack of 20 z-sections was
collected every 15 min in the YFP channel
(green), and one image was taken with differ-
ential interference contrast (DIC). The pro-
jected z-stacks were merged to the respective
DIC image. Bar, 5 M. The level of PML and
p53 proteins were analyzed during arsenic
and cycloheximide treatment by SDS PAGE
followed by Western Blotting with chicken
PML and mouse p53 antibodies (B). (C) Mon-
itoring of RNF4 and p53 protein levels during
cycloheximide treatment. PML-YFP HeLa
cells were incubated with 50 g/ml cyclohex-
imide, and whole cell extracts were analyzed
at different times by SDS PAGE followed by
Western Blotting with rabbit RNF4 and
mouse p53 antibodies. (D) Arsenic does not
alter the level of RNF4 protein. Total cells
extracts from HeLa PML-YFP exposed to ar-
senic for 24 h were analyzed by SDS PAGE
followed by Western blot with a rabbit anti-
RNF4 antibody to follow the level of RNF4
during arsenic treatement. (E) Quantiﬁcation
of Rnf4 transcripts during arsenic treatment.
Total RNA from HeLa PML-YFP stable cells
exposed to 1 M arsenic for 24 h was ex-
tracted and real-time quantitative PCR was
performed with speciﬁc gene primers for
RNF4 and actin. The graph shows the relative
mRNF4 level after normalization to actin
transcripts.
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body revealed that PML-YFP was expressed at levels similar to
that of endogenous PML and was of the predicted molecular
weight (Figure 1B). FACS analysis after propidium iodide
staining indicated that the PML-YFP and parental HeLa cells
had a comparable cell cycle proﬁle (Figure 1E).
Kinetics of Arsenic-Induced RNF4-Mediated PML
Degradation
To establish the kinetics of arsenic-induced degradation of
PML in the presence or absence of RFN4, PML-YFP HeLa
cells were transfected with either a pool of siRNA against
human RNF4 or a pool of nontargeting SiRNA as a negative
control. Depletion of RNF4 was conﬁrmed by Western blot-
ting using a rabbit anti-RNF4 antibody (Figure 2C). To fol-
low the degradation of PML in real time, PML-YFP HeLa
cells were exposed to arsenic (As2O3) and YFP ﬂuorescence
quantiﬁed at 15-min intervals over an 18-h period by ﬂuo-
rescence microscopy (Figure 2A, full movie is available in
Supplemental Figure S1, A and B). The position of PML NBs
within the cells during arsenic treatment was monitored by
differential interference contrast microscopy (DIC) and ﬂu-
orescence intensity of multiple individual PML bodies was
quantiﬁed at each time point (Figure 2B).
As we have previously reported (Tatham et al., 2008) the
number and the size of PML bodies were increased in cells
depleted of RNF4 (Figure 2A and Supplemental Figure S1D).
This indicates that in the PML-YFP HeLa cells the level of
endogenous RNF4 is sufﬁcient to regulate the level and
localization of both endogenous PML and PML-YFP.
In cells treated with arsenic, the ﬂuorescence intensity of
nuclear body associated PML was increased within one hour
Figure 5. Arsenic-induced SUMO-depen-
dent recruitment of RNF4 into PML nuclear
bodies. (A and B) Subcellular localization of
RNF4 during arsenic treatment. (A) HeLa
cells were exposed to 1 uM arsenic for 60 min
and the localization of endogenous PML and
RNF4 determined by immunoﬂuorescence
using 5E10 mAb to PML and an afﬁnity pu-
riﬁed chicken antibody to RNF4. (B) HeLa
cells were transfected with ﬂuorescent-tagged
RNF4 plasmids expressing either wild type
RNF4-YFP or protein mutated in the RING
domain of RNF4 (RNF4-YFP-CS1) or RNF4
with all 4 SIMs mutated (RNF4-delta SIM).
YFP ﬂuorescence (green) was monitored in
real-time microscopy after arsenic treatment
by collecting a stack of 20 z-sections every 10
min for 3 h. Images represent a projection of
the z-sections. (C) Quantiﬁcation of RNF4-
YFP ﬂuorescence was determined by measur-
ing the difference of ﬂuorescence intensity be-
tween one PML body and a region outside the
nucleoplasm. The graph shows means values
of the relative ﬂuorescence intensity after nor-
malization from 10 cells. (D) Arsenic-induced
recruitment of RNF4 in HeLa PML-YFP stable
cells. PML-YFP HeLa cells were transfected
with a RNF4-CFP plasmid and ﬂuorescence
monitored for 2 h after addition of arsenic.
Images shows the recruitment of RNF4-CFP
(blue) within PML bodies (green). Bar, 5 M.
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Molecular Biology of the Cell 4232(Figure 2, A and B). This is consistent with a previous report
(Lallemand-Breitenbach et al., 2001) showing that arsenic
induces a rapid SUMO-dependent recruitment of nucleo-
plasmic PML into nuclear bodies. This recruitment was in-
dependent of RNF4 and suggests that RNF4 is not involved
in the recruitment of PML into nuclear bodies at early stage
of the arsenic response. After4ho fexposure to arsenic, the
ﬂuorescence intensity of PML-YFP in cells containing RNF4
declines, until at 15 h the signal is almost undetectable
(Figure 2, A and B). Western blot analysis reveals that this is
a consequence of arsenic-induced degradation of PML (Fig-
ure 2C). However, in RNF4-depleted cells, PML-YFP ﬂuo-
rescence in nuclear bodies increased progressively in re-
sponse to arsenic leading to the accumulation of PML-YFP in
large nuclear bodies (Figure 2, A and B). Finally, we have
used HeLa clone 6 cells (Tatham et al., 2008), which are
depleted of RNF4, to establish another cell line expressing a
cyan ﬂuorescent version of PML isoform III (PML-CFP).
When PML-CFP HeLa clone 6 (RNF4 depleted) and PML-
YFP HeLa cells are mixed and grown on the same coverslip
then exposed to arsenic this allows the simultaneous analy-
sis of PML degradation in the presence and absence of RNF4
under identical conditions. This conﬁrms (Supplemental
Figure S1C) that RNF4 induces the degradation of PML-YFP
in response to arsenic, while in cells lacking RNF4, arsenic
induces the continuous accumulation of PML-CFP in nu-
clear bodies. To analyze the posttranslational modiﬁcations
that initiate these processes PML-YFP HeLa cells were ex-
posed to arsenic for 1 h and PML-YFP proteins collected by
immunoprecipitation. Analysis of such immunoprecipitates
by Western blotting indicated that 1 h after exposure of cells
to arsenic, PML-YFP displayed an increased apparent mo-
lecular weight as a consequence of extensive modiﬁcation by
SUMO-1, SUMO-2, and ubiquitin (Figure 2D).
Kinetics of SUMO-2 Redistribution in Response to
Arsenic
To better understand the role of SUMO in the nuclear dy-
namics of PML, the distribution of SUMO-2 during arsenic
treatment, in the presence or the absence of RNF4, was
followed by real-time imaging (Figure 3). HeLa cells stably
expressing YFP-SUMO-2 were transfected with either a pool
of siRNA against human RNF4 or a pool of nontargeting
siRNA as a negative control (Figure 3, A and B). After 48 h,
cells were incubated with arsenic (As2O3) over a 15-h period
to follow the localization of SUMO-2 (Figure 3B). In the
presence of RNF4, YFP-SUMO-2 is initially present both in
the nucleoplasm and in PML bodies. After exposure of cells
to arsenic the PML body associated YFP-SUMO-2 is lost and
YFP-SUMO-2 redistributes to the nucleoplasm (Figure 3C).
Figure 6. Comparison of RNF 4 and PML
mobility. (A) The mobility of RNF4 and PML
III was analyzed by Fluorescence Recovery
After Photobleaching (FRAP) on living HeLa
PML-YFP stable cells or HeLa cells trans-
fected with RNF4-YFP. Circled areas (red)
containing one PML NB were bleached to
background level and the ﬂuorescence recov-
ery of RNF4 and PML was monitored for 11 s
and 10 min, respectively. A single image was
taken for RNF4 at selected time point,
whereas a stack of 20 sections was collected
every minute for PML. Images for PML rep-
resent a projection of z-sections. Bar, 5 m. (B
and C) Quantiﬁcation of FRAP experiments.
The ﬂuorescence intensity in the bleached
area was normalized to the change in ﬂuores-
cence intensity outside the nucleus and in an
unbleached PML NB. The graphs (B and C)
show the mean values and standard devia-
tions of relative prebleach and postbleach in-
tensities of ten PML Nbs which was plotted
over time in sec (B) or in min (C).
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nuclear bodies and after exposure of cells to arsenic YFP-
SUMO-2 further accumulates in these large brightly staining
bodies and also begins to accumulate adjacent to nucleoli
(Figure 3C and Supplemental Figure S2), as shown by im-
munostaining with an antinucleolin antibody. In some YFP-
SUMO-2 expressing cells depletion of RNF4 results in the
formation of “peanut” shaped nuclei, the origin of which is
at present unclear.
Continued Protein Synthesis Is Required for
Arsenic-Induced Degradation of PML
It has been previously reported that arsenic-induced apo-
ptosis could be blocked by the protein synthesis inhibitor
cycloheximide (Park et al., 2001). To establish whether cy-
cloheximide blocked arsenic-induced PML degradation,
PML-YFP HeLa cells were incubated with either arsenic or
with arsenic and cycloheximide. YFP ﬂuorescence was fol-
lowed by ﬂuorescence microscopy and the levels of PML
were monitored by Western blot (Figure 4, A and B). We also
monitored the levels of the rapidly turning over protein, p53
(Figure 4B). As expected arsenic induced degradation of
PML-YFP but in the presence of cycloheximide arsenic treat-
ment did not fully induce PML-YFP degradation (Figure 4,
A and B), suggesting that the continued synthesis of a spe-
ciﬁc protein(s) was required for arsenic-induced PML deg-
radation. As RNF4 is required for arsenic-induced PML
degradation, the levels of this protein were monitored by
Western blotting after treatment of the cells with cyclohex-
imide (Figure 4C). Treatment with cycloheximide led to
decreased levels of RNF4, until after 3 h RNF4 was unde-
tectable (Figure 4C). By comparison, p53 levels were re-
duced after 15 min and were almost undetectable 1 h after
exposure to cycloheximide (Figure 4, B and C). Reduction in
the levels of RNF4, as a consequence of cycloheximide treat-
ment, is a likely explanation for the inhibition of arsenic-in-
duced degradation of PML by cycloheximide. This is consistent
with the observation that cycloheximide did not block the
initial RNF4-independent accumulation of PML-YFP in nu-
clear bodies. As RNF4 levels are critical for arsenic-induced
PML degradation, we monitored the levels of RNF4 protein by
Western blotting and mRNA by quantitative PCR. Over the
24-h period of arsenic treatment neither RNF4 protein nor
mRNA levels were altered (Figure 4, D and E).
Arsenic Induced SUMO-Dependent Recruitment of RNF4
to PML Nuclear Bodies
Having shown that RNF4 was essential to induce PML
degradation, it was important to understand how PML is
targeted by RNF4. Immunoﬂuorescence microscopy was
used to establish the subcellular localization of endogenous
RNF4 and how this is changed after arsenic treatment. In the
absence of arsenic, RNF4 is diffusely distributed through-
out the nucleus, but after exposure of cells to arsenic
RNF4 accumulates in PML bodies (Figure 5A). To follow
this recruitment of RNF4 into PML bodies in real time, cells
expressing RNF4-YFP were exposed to arsenic and the sub-
cellular localization of RNF4 followed by ﬂuorescence mi-
croscopy. RNF4-YFP is rapidly recruited into nuclear bodies
in response to arsenic (Figure 5B and Supplemental Figure
S2A). This recruitment of RNF4-YFP into nuclear bodies was
not dependent on the E3 ubiquitin ligase activity of RNF4, as
RNF4 containing a RING domain mutation was recruited
into nuclear bodies with similar kinetics to that of RNF4 wt
(Figure 5, B and C). However, recruitment of RNF4-YFP into
nuclear bodies was SUMO-dependent, as a version of RNF4
Figure 7. RNF4 does not affect PML trafﬁck-
ing between PML and nucleoplasm. (A–C)
Effect of RNF4 on PML mobility. (A) FRAP
experiments were performed on HeLa PML-
YFP stable cells transfected with a nontarget
siRNA (siNT) or an siRNA against RNF4
(siRNF4). Images represent projection of z-
sections of PML NBs before and after photo-
bleaching over a period of 10 min. Bar, 5 M.
(B) Depletion of RNF4 was controled by SDS
PAGE followed by Western blot with rabbit
RNF4 antibody. (C) The graph shows the
mean values and standard deviations of rela-
tive prebleach and postbleach intensities of
ten PML Nbs as described in Figure 6.
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recruited into nuclear bodies in response to arsenic (Figure
5, B and C and Supplemental Figure S2B). To demonstrate
that the nuclear bodies into which RNF4 was recruited were
indeed PML bodies, RNF4-CFP was introduced into PML-
YFP HeLa cells and the localization of the ﬂuorescent pro-
teins following arsenic treatment was monitored by ﬂuores-
cence microscopy (Figure 5D and Supplemental Figure S2, C
and D). RNF4-CFP rapidly accumulated in the same nuclear
bodies that were marked by PML-YFP, indicating that ar-
senic induced the recruitment of RNF4 into PML nuclear
bodies.
To establish the kinetics of RNF4 and PML trafﬁcking
through PML bodies we analyzed the mobility of RNF4 and
PML III by Fluorescence Recovery After Photobleaching
(FRAP). RNF4-YFP shuttles very quickly between PML bodies
and nucleoplasm as it takes 10 s to fully recover after pho-
tobleaching of PML bodies (Figure 6, A and B). In contrast,
recruitment of PML-YFP into PML bodies from the nucleo-
plasm is rather slow as full recovery after photobleaching takes
almost 10 min (Figure 6, A–C). This slow uptake of PML
isoform III into nuclear bodies is entirely consistent with pre-
viously published data (Weidtkamp-Peters et al., 2008).
Role of RNF4 in the Recruitment of PML into Nuclear
Bodies
Arsenic treatment promotes recruitment of nucleoplasmic
PML into PML nuclear bodies. In cells where RNF4 has been
depleted, PML is already concentrated into PML bodies. To
establish the role of RNF4 in the nuclear dynamics of PML
we used FRAP. Initially, we monitored the dynamics of PML
in the presence and the absence of RNF4 in PML-YFP HeLa
cells. A region containing a single PML body was bleached
to background level and ﬂuorescence recovery was moni-
tored for 10 min. Fluorescence recovery was similar in PML-
YFP HeLa cells that had been depleted of RNF4 by siRNA
compared with the same cells treated with a nontargeting
siRNA (Figure 7, A–C). Thus it appears that RNF4 does not
affect the trafﬁcking of PML III between nucleoplasm and
PML bodies. To establish the role of RNF4 in the partitioning
of PML between the nucleoplasm and nuclear bodies in
response to arsenic, we treated PML-YFP HeLa cells with
siRNA to RNF4 or with a nontargeting control siRNA and
used FRAP to monitor the uptake of PML-YFP into nuclear
bodies at various times after exposure of the cells to arsenic
(Figure 8A). While arsenic progressively decreases the up-
take of PML-YFP into nuclear bodies, this is entirely inde-
pendent of RNF4 as the rate of recovery is indistinguishable
in cells treated with siRNA to RNF4 and cells treated with a
nontargeting siRNA (Figure 8, B and C).
In Vivo Interaction of RNF4 with SUMO-2 during Arsenic
Treatment
To establish that PML bodies were the sites of interaction
between RNF4 and SUMO-2, we performed Fluorescence
Resonance Energy transfer (FRET) in living cells (Figure 9).
FRET is based on the ability of a higher-energy donor ﬂu-
orophore (CFP) to transfer energy to a lower-energy accep-
Figure 8. Effect of RNF4 on PML mobility
during arsenic treatment. (A–C) RNF4 does
not affect PML mobility during arsenic treat-
ment. (A) PML ﬂuorescence recovery after
photobleaching was determined after arsenic
treatment in HeLa PML-YFP stable cells
transfected with a nontarget siRNA (siNT) or
a siRNA against RNF4 (siRNF4). PML NBs
were bleached after a period of 10, 20, 30, or
40 min of incubation with arsenic and ﬂuo-
rescence recovery was monitored over a pe-
riod of 10 min for each time point. Images
represent projection of z-sections of PML NBs
before and after photobleaching over a period
of 10 min. Bar, 5 M. (B and C) The graphs
show the mean values and standard devia-
tions of relative prebleach and postbleach in-
tensities of PML NBs from ﬁve different ex-
periments.
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photobleaching the acceptor molecule such that energy from
the donor can no longer be transferred to the acceptor. This
leads to an increase in ﬂuorescence of the donor molecule.
Therefore, YFP-SUMO-2 and RNF4-CFP were coexpressed
in HeLa cells and a region of interest containing YFP-
SUMO-2 within a PML body was irridiated without bleach-
ing RNF4-CFP (Figure 9, A and B). Fluorescence intensity of
the donor molecule (RNF4-CFP) was then measured in non-
treated cells or in cells treated with arsenic for 6 h. Interest-
ingly, an increase in ﬂuorescence of RNF4-CFP was only
detected when cells were treated with arsenic, suggesting
that the formation of long polySUMO-2 chains upon arsenic
treatment represents a scaffold for RNF4 to interact with
SUMO-2 (Figure 9, A–C). In the absence of arsenic, the CFP
signal remained constant, indicating that RNF4 does not
stably interact with SUMO-2 in PML bodies but diffuses
quickly between nucleoplasm and PML bodies. Also, pho-
tobleaching of YFP-SUMO-2 within the nucleoplasm in cells
either nontreated or treated with arsenic did not lead to an
increase of RNF4-CFP ﬂuorescence, strongly suggesting that
RNF4 interacts stably with SUMO-2 only in PML bodies
(data not shown). This is consistent with our observation
showing the recruitment of RNF4 in real time upon arsenic
treatment. Attempts to use FRET to demonstrate an interac-
tion between RNF4 and PML either in the absence or pres-
ence of arsenic were unsuccessful, irrespective of whether
the ﬂuorescent protein was fused to the C or N terminus of
RNF4 and PML (data not shown). These data suggest that
RNF4 interacts with polySUMO chains attached to PML,
rather than directly with PML.
DISCUSSION
The fate of PML protein, and the nuclear bodies in which it
resides, have been extensively studied as fusion of the PML
protein to the RAR is the cause of Acute Promyelocytic
Leukemia. An effective treatment for this disease is the
Figure 9. In vivo interaction of RNF4-CFP
with YFP-SUMO-2. (A) Fluorescence Reso-
nance Energy Transfer (FRET) acceptor pho-
tobleaching was done on HeLa cells cotrans-
fected with plasmids expressing RNF4-CFP
and YFP-SUMO-2 either untreated or treated
with 1  arsenic. Images shows sequential
CFP and YFP ﬂuorescence collected before
and after photobleaching of a circled area
(red) containing one PML NB. Bar 5 M. (B)
The graph shows the CFP and YFP ﬂuores-
cence intensities of bleached and nonbleached
nuclear areas of similar-sizes from cells ex-
posed to arsenic for 6 h. (C) FRET efﬁciencies
during arsenic treatment. The graph shows
the mean values and SD of the FRET efﬁ-
ciency from ﬁve independent experiments.
FRET efﬁciency is represented as the percent
of increase of prebleach CFP ﬂuorescence af-
ter YFP photobleaching of one PML NB.
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degradation of the PML-RAR fusion protein. Immediately
after arsenic treatment, the PML protein becomes poly-
SUMO modiﬁed and it is this modiﬁcation that recruits the
SUMO-speciﬁc ubiquitin E3 ligase RNF4 (Tatham et al., 2008;
Lallemand-Breitenbach et al., 2008). Subsequent ubiquityla-
tion of SUMO-modiﬁed PML results in its proteasomal deg-
radation. To gain insight into the details of PML degradation
we established HeLa cells that express PMLIII-YFP at close
to endogenous levels. When these cells are exposed to ar-
senic the PML-YFP fusion protein undergoes SUMO-depen-
dent ubiquitin-mediated proteolysis and is degraded over a
similar timescale to that of the endogenous protein. Here we
have used real-time ﬂuorescence microscopy to establish the
dynamics of PML and RNF4 recruitment into PML bodies
when cells are exposed to arsenic. This revealed that RNF4
does not affect residence time of PML in PML NBs, as the
recovery of PML III-YFP into NBs after photobleaching does
not change when RNF4 expression is ablated by siRNA
(Figure 7). Exposure of cells to arsenic leads to a rapid
decrease in the mobility of PML-YFP, which was again
independent of the presence of RNF4 (Figure 8). This “ﬁx-
ing” of PML into PML NBs occurred 60 min after addition
of arsenic and was coincident with a dramatic increase in the
SUMO modiﬁcation status of PMLIII-YFP (Figure 2). Re-
cently, it has been proposed that PML immobilization in
nuclear bodies could arise from the arsenic-induced cross-
linking of PML, as a consequence of direct arsenic-mediated,
cross-linking of cysteine residues in PML, and oxidation-
induced formation of disulphide bonds. It is thought that
these changes promote multimerization of PML, leading to
enhanced recruitment of Ubc9 and thus increased SUMOy-
lation of PML (Jeanne et al., 2010). As the form of PML that
cannot be SUMO modiﬁed displays a very low residence
time in PML bodies (Weidtkamp-Peters et al., 2008), it seems
likely that the increased residence time of PML in NBs after
arsenic treatment is a consequence of the observed PML
SUMO modiﬁcation.
In the absence of arsenic, RNF4-CFP appears to be pre-
dominantly nucleoplasmic although a small proportion ap-
pears to be localized to PML NB (Figure 5). After addition of
arsenic, RNF4-CFP is recruited from the nucleoplasm into
PML bodies with similar kinetics to the recruitment of
PMLIII-YFP into nuclear bodies (Figure 5) and paralleling
the rapid arsenic-induced SUMO modiﬁcation of PML (Fig-
ure 2). Immunoﬂuorescence studies with an antibody to
RNF4 indicated that the endogenous RNF4 protein also
undergoes a similar arsenic-dependent relocalization from
the nucleoplasm to PML nuclear bodies (Figure 5A). This
arsenic-induced recruitment of RNF4-CFP into PML nuclear
bodies is entirely SUMO-dependent, because a form of
RNF4 that is unable to bind SUMO is not recruited in re-
sponse to arsenic (Figure 5). As RNF4 binds speciﬁcally to
polySUMO chains, these data suggest that arsenic-induced
modiﬁcation of PML with polySUMO chains occurs in PML
nuclear bodies. This contention is supported by the FRET
experiments showing that FRET between YFP-SUMO-2 and
RNF4-CFP is detected in PML bodies, but not in the nucle-
oplasm (Figure 9). Although the sites at which polySUMO
chains are formed have not been previously localized, these
data are consistent with previously published work suggest-
ing that PML bodies are sites of SUMO modiﬁcation (Lalle-
mand-Breitenbach et al., 2001; Quimby et al., 2006). While
FRET allowed the detection of a robust interaction between
RNF4 and SUMO-2 in PML bodies after arsenic treatment
we were unable to detect any interaction between RNF4-
CFP and PMLIII-YFP using this approach, despite using
different combinations of plasmid constructs to express YFP
or CFP at the amino or carboxy terminus of the proteins
(data not shown). These data are in line with the known
protein interaction properties of RNF4 where the conserved,
multiple SIMs in its N terminus bind to polySUMO chains
(Tatham et al., 2008). While it is possible that our inability to
detect FRET between RNF4 and PML is due to an unfavor-
able steric arrangement of the CFP and YFP ﬂuorophores, a
more likely interpretation of the data are that RNF4-CFP
does not interact with PMLIII-YFP, but binds to the long
polySUMO chains on PML, thus increasing the distance
between the YFP and CFP ﬂuorophores out with the range at
which a FRET signal can be detected. However these data do
not appear to be consistent with a recent report (Percheran-
cier et al., 2009) in which BRET was used to detect an
interaction between PML luciferase and YFP-RNF4 upon
addition of luciferase substrate. This interaction increased
after arsenic addition but was dependent on PML SUMOy-
lation and may be explained by an indirect interaction via
SUMO and the greater distance over which BRET can be
monitored. We have previously demonstrated that RNF4
was responsible for ubiquitylation of SUMO-modiﬁed PML
(Tatham et al., 2008). Thus, the direct result of RNF4 recruit-
ment into NBs by polySUMO-modiﬁed PML is likely to be
the ubiquitylation of polySUMO chains attached to PML
within the NBs. As the ultimate consequence of arsenic
treatment is the degradation of PML, the most likely site of
PML degradation is within the PML body. A number of
observations are consistent with this hypothesis. It has pre-
Figure 10. Model for the subnuclear trafﬁcking of PML and RNF4 in response to arsenic. Details of the model are described in the text.
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PML bodies in the presence of proteasome inhibitors (Bailey
and O’Hare, 2005) and that arsenic-induced degradation of
PML is blocked by proteasome inhibition, with the PML
protein accumulating in PML NBs (Lallemand-Breitenbach
et al., 2008). Immunoﬂuorescence studies have revealed that
components of the proteasome are present in PML bodies
(Lallemand-Breitenbach et al., 2001; Fabunmi et al., 2001;
Lafarga et al., 2002; Rockel et al., 2005). Most dramatically,
siRNA-mediated depletion of RNF4, the ubiquitin E3 ligase
responsible for PML degradation, leads to the arsenic-in-
duced accumulation of PML in PML NBs (Figure 2). On the
basis of our ﬁndings reported here we propose that arsenic
leads to release of an activity that generates polySUMO
chains on NB-associated PML. This could be due to inhibi-
tion of SUMO-speciﬁc proteases, activation of a distinct
SUMO E3 ligase such as Ran BP2 (Saitoh et al., 2006), or
activation of an intrinsic SUMO E3 ligase associated with
PML only observed in yeast so far (Quimby et al., 2006).
Interestingly, it has been shown recently that low doses of
H2O2 increase SENP3 levels that in turn reduce the number
of PML bodies due to the deconjugation of SUMO-2/3 from
PML (Han et al., 2010). However, it remains to be deter-
mined whether arsenic interferes with the expression of
speciﬁc SUMO proteases. On the basis of these data we have
formulated a working model for the mechanism of action of
arsenic (Figure 10). Before arsenic treatment PML shuttles in,
and out, of nuclear bodies. However, upon the addition of
arsenic nuclear body-associated PML undergoes rapid poly-
SUMOylation which “ﬁxes” the modiﬁed PML in the nu-
clear bodies. In the absence of RNF4 there is continued
movement of PML into nuclear bodies where it undergoes
arsenic-induced polySUMO modiﬁcation. However, as it
cannot be ubiquitylated it is not degraded and the poly-
SUMO chain ﬁxes it in the nuclear bodies, precluding its
return to the nucleoplasm. In the presence of RNF4 the
polySUMO chains attached to PML are ubiquitylated, and
this assembly is targeted to nuclear body-associated protea-
somes where PML undergoes degradation. Although we
have not addressed this question directly it seems likely that
the polySUMO, polyUbiquitin hybrid chains are removed
from PML before its degradation.
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